2021
Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials
Magid-Bernstein JR, Li Y, Cho SM, Piran PJ, Roh DJ, Gupta A, Shoamanesh A, Merkler A, Zhang C, Avadhani R, Montano N, Iadecola C, Falcone G, Sheth K, Qureshi AI, Rosand J, Goldstein J, Awad I, Hanley D, Kamel H, Ziai WC, Murthy SB. Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials. Neurology 2021, 98: e1013-e1020. PMID: 34937780, PMCID: PMC8967392, DOI: 10.1212/wnl.0000000000013247.Peer-Reviewed Original ResearchConceptsSmaller ICH volumeCerebral microbleedsSmall vessel diseaseIntracerebral hemorrhageHematoma expansionHematoma characteristicsICH volumeVessel diseaseNumber of CMBsSmaller baseline hematoma volumesUnderlying small vessel diseasePresence of CMBsCerebral small vessel diseaseAdmission ICH volumeMISTIE III trialPresence of microbleedsClass II evidencePhase 3 trialSeverity of leukoaraiosisPrimary intracerebral hemorrhageBaseline hematoma volumeIndividual patient dataBrain MRI scansLogistic regression modelsAntihypertensive treatment
2019
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original ResearchConceptsBetter clinical outcomesPhase 2 trialSerious adverse eventsRankin Scale scorePlacebo groupIntracerebral hemorrhagePrimary outcomeClinical outcomesDay 90Deferoxamine mesylateModified intentionTreat populationAdverse eventsUS National InstitutesDouble-blind phase 2 trialScale scorePhase 3 efficacy trialsModified Rankin Scale scoreEfficacy of deferoxaminePhase 3 trialSupratentorial intracerebral hemorrhageAbsolute risk differenceProportion of participantsNational InstituteIron chelator deferoxamineEfficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
Hanley D, Thompson R, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo S, Bistran-Hall A, Gandhi D, Mould W, Ullman N, Ali H, Carhuapoma J, Kase C, Lees K, Dawson J, Wilson A, Betz J, Sugar E, Hao Y, Avadhani R, Caron J, Harrigan M, Carlson A, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine M, Patel H, Dodd R, Camarata P, Wolfe S, Stadnik A, Money P, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum J, Wang W, Anderson C, Mendelow A, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad I, Investigators M, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Altschul D, Amin-Hanjani S, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Baguena M, Baker A, Barrer S, Becker K, Bergman T, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Cao B, Cao Y, Carrion-Penagos J, Chalela J, Chang T, Chorro I, Chowdhry S, Corral L, Csiba L, Davies J, Díaz A, Derdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gress D, Gu E, Hall C, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Keric N, Kerz T, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mohan K, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Perla K, Pollack A, Polster S, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rybinnik I, Sanchez B, Sansing L, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Szabo K, Tamayo G, Tanczos K, Taussky P, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ungar L, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vollmer D, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wrencher M, Wright S, Xu Y, Yanase L, Yi X, Yu Z, Zomorodi A. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. The Lancet 2019, 393: 1021-1032. PMID: 30739747, PMCID: PMC6894906, DOI: 10.1016/s0140-6736(19)30195-3.Peer-Reviewed Original ResearchConceptsStandard medical care groupMedical care groupStandard medical carePhase 3 trialProportion of patientsSerious adverse eventsSupratentorial intracerebral hemorrhageCare groupIntracerebral hemorrhageMedical careAdverse eventsMRS scoreFunctional outcomeComputer-generated number sequenceModified Rankin Scale scoreInvasive catheter evacuationPrespecified baseline covariatesPrimary efficacy outcomeLarge intracerebral hemorrhageGood functional outcomeRankin Scale scoreNumber of patientsIntracerebral hemorrhage evacuationLogistic regression modelsBlinded endpoint